203 related articles for article (PubMed ID: 35306154)
1. Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis.
Lang Kuhs KA; Faden DL; Chen L; Smith DK; Pinheiro M; Wood CB; Davis S; Yeager M; Boland JF; Cullen M; Steinberg M; Bass S; Wang X; Liu P; Mehrad M; Tucker T; Lewis JS; Ferris RL; Mirabello L
Ann Oncol; 2022 Jun; 33(6):638-648. PubMed ID: 35306154
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.
Rettig EM; Wentz A; Posner MR; Gross ND; Haddad RI; Gillison ML; Fakhry C; Quon H; Sikora AG; Stott WJ; Lorch JH; Gourin CG; Guo Y; Xiao W; Miles BA; Richmon JD; Andersen PE; Misiukiewicz KJ; Chung CH; Gerber JE; Rajan SD; D'Souza G
JAMA Oncol; 2015 Oct; 1(7):907-15. PubMed ID: 26226294
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan.
Yoshida T; Ogawa T; Nakanome A; Ohkoshi A; Ishii R; Higashi K; Ishikawa T; Katori Y; Furukawa T
Auris Nasus Larynx; 2022 Dec; 49(6):1033-1041. PubMed ID: 35491282
[TBL] [Abstract][Full Text] [Related]
5. Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
Robbins HA; Ferreiro-Iglesias A; Waterboer T; Brenner N; Nygard M; Bender N; Schroeder L; Hildesheim A; Pawlita M; D'Souza G; Visvanathan K; Langseth H; Schlecht NF; Tinker LF; Agalliu I; Wassertheil-Smoller S; Ness-Jensen E; Hveem K; Grioni S; Kaaks R; Sánchez MJ; Weiderpass E; Giles GG; Milne RL; Cai Q; Blot WJ; Zheng W; Weinstein SJ; Albanes D; Huang WY; Freedman ND; Kreimer AR; Johansson M; Brennan P
J Clin Oncol; 2022 Nov; 40(31):3613-3622. PubMed ID: 35700419
[TBL] [Abstract][Full Text] [Related]
6. Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000.
Whitmarsh A; Pring M; Thomas SJ; Waylen A; Ness AR; Dudding T; Pawlita M; Brenner N; Waterboer T; Schroeder L
Cancer; 2021 Jul; 127(14):2442-2452. PubMed ID: 33721332
[TBL] [Abstract][Full Text] [Related]
7. HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx.
Dahlstrom KR; Anderson KS; Cheng JN; Chowell D; Li G; Posner M; Sturgis EM
Clin Cancer Res; 2015 Jun; 21(12):2861-9. PubMed ID: 26078432
[TBL] [Abstract][Full Text] [Related]
8. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
Anderson KS; Dahlstrom KR; Cheng JN; Alam R; Li G; Wei Q; Gross ND; Chowell D; Posner M; Sturgis EM
Oral Oncol; 2015 Jul; 51(7):662-7. PubMed ID: 25957822
[TBL] [Abstract][Full Text] [Related]
9. Predictors of oropharyngeal cancer survival in Europe.
Anantharaman D; Billot A; Waterboer T; Gheit T; Abedi-Ardekani B; Lagiou P; Lagiou A; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Polesel J; Simonato L; Alemany L; Mena Cervigon M; Macfarlane TV; Znaor A; Thomson PJ; Robinson M; Canova C; Conway DI; Wright S; Healy CM; Toner ME; Pawlita M; Tommasino M; Brennan P
Oral Oncol; 2018 Jun; 81():89-94. PubMed ID: 29884419
[TBL] [Abstract][Full Text] [Related]
10. Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV-related oropharyngeal cancer and cancer of unknown primary.
Tanaka H; Suzuki M; Takemoto N; Fukusumi T; Eguchi H; Takai E; Kanai H; Tatsumi M; Horie M; Takenaka Y; Yachida S; Inohara H
Int J Cancer; 2022 Jan; 150(1):174-186. PubMed ID: 34486724
[TBL] [Abstract][Full Text] [Related]
11. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated With Persistence and Clearance of High-Risk Oral Human Papillomavirus (HPV) Among Participants in the HPV Infection in Men (HIM) Study.
Bettampadi D; Sirak BA; Abrahamsen ME; Reich RR; Villa LL; Ponce EL; Giuliano AR
Clin Infect Dis; 2021 Nov; 73(9):e3227-e3234. PubMed ID: 33173937
[TBL] [Abstract][Full Text] [Related]
13. High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.
Prétet JL; Dalstein V; Touzé A; Beby-Defaux A; Soussan P; Jacquin É; Birembaut P; Clavel C; Mougin C; Rousseau A; Lacau Saint Guily J;
Clin Exp Med; 2023 Feb; 23(1):87-96. PubMed ID: 35199231
[TBL] [Abstract][Full Text] [Related]
14. Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.
Fakhry C; Qualliotine JR; Zhang Z; Agrawal N; Gaykalova DA; Bishop JA; Subramaniam RM; Koch WM; Chung CH; Eisele DW; Califano J; Viscidi RP
Cancer Prev Res (Phila); 2016 Feb; 9(2):135-41. PubMed ID: 26701665
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.
Zhang Y; Waterboer T; Haddad RI; Miles BA; Wentz A; Gross ND; Fakhry C; Quon H; Lorch JH; Gourin CG; Clayburgh D; Misiukiewicz KJ; Richmon JD; Andersen PE; Posner MR; D'Souza G
Oral Oncol; 2017 Apr; 67():77-82. PubMed ID: 28351584
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes.
Varier I; Keeley BR; Krupar R; Patsias A; Dong J; Gupta N; Parasher AK; Genden EM; Miles BA; Teng M; Bakst RL; Gupta V; Misiukiewicz KJ; Chiao EY; Scheurer ME; Laban S; Zhang D; Ye F; Cui M; Demicco EG; Posner MR; Sikora AG
Head Neck; 2016 Sep; 38(9):1330-7. PubMed ID: 27080140
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and distribution of human papillomavirus (HPV) in Luoyang city of Henan province during 2015-2021 and the genetic variability of HPV16 and 52.
Wang X; Han S; Li X; Wang X; Wang S; Ma L
Virol J; 2022 Mar; 19(1):37. PubMed ID: 35246180
[TBL] [Abstract][Full Text] [Related]
18. Telomere length in peripheral blood lymphocytes contributes to the development of HPV-associated oropharyngeal carcinoma.
Zhang Y; Sturgis EM; Dahlstrom KR; Wen J; Liu H; Wei Q; Li G; Liu Z
Cancer Res; 2013 Oct; 73(19):5996-6003. PubMed ID: 23928994
[TBL] [Abstract][Full Text] [Related]
19. Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer.
Drake VE; Fakhry C; Windon MJ; Stewart CM; Akst L; Hillel A; Chien W; Ha P; Miles B; Gourin CG; Mandal R; Mydlarz WK; Rooper L; Troy T; Yavvari S; Waterboer T; Brenner N; Eisele DW; D'Souza G
Cancer; 2021 Apr; 127(7):1029-1038. PubMed ID: 33426652
[TBL] [Abstract][Full Text] [Related]
20. Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer.
Dickey BL; Nedjai B; Preece MD; Schell MJ; Boulware D; Whiting J; Sirak B; Abrahamsen M; Isaacs-Soriano KA; Kennedy K; Chung CH; Giuliano AR
Cancer Med; 2022 Oct; 11(20):3735-3742. PubMed ID: 35619332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
